Background/Advantages: Since May 2013 ocriplasmin (Jetrea, Alcon) has been available on the German market for the treatment of vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns. The main aim of this study was to treat a more homogenous group of patients with specific baseline characteristics with ocriplasmin, and to compare the results with those of previous trials. Patient...

Read More